Literature DB >> 16285990

Apolipoprotein A-I and the molecular variant apoA-I(Milano): evaluation of the antiatherogenic effects in knock-in mouse model.

Cinzia Parolini1, Giulia Chiesa, Elaine Gong, Silvia Caligari, Miriam M Cortese, Teiichiro Koga, Trudy M Forte, Edward M Rubin.   

Abstract

No evidence of premature vascular disease is found in apolipoprotein A-I(Milano) (apoA-I(M)) human carriers, despite very low high density lipoprotein (HDL) cholesterol levels. Whether apoA-I(M) may impart a "gain of function" in atherosclerosis protection compared to wild-type apoA-I is hotly debated. To address this question, knock-in mice expressing human apoA-I or apoA-I(M) were crossed with atherosclerosis-susceptible mice expressing the human apoB/A-II transgene (h-B/A-II/A-I(Hu/Hu) and h-B/A-II/A-I(M)(Hu/Hu)). On a chow diet, h-B/A-II/A-I(M)(Hu/Hu) mice were characterized by low HDL cholesterol levels compared to h-B/A-II/A-I(Hu/Hu) mice (35.65+/-8.00 mg/dl versus 58.09+/-13.50mg/dl, respectively; p<0.005). Gender differences in response to high fat diet were observed in both h-B/A-II/A-I(M)(Hu/Hu) and h-B/A-II/A-I(Hu/Hu) lines. h-B/A-II/A-I(M)(Hu/Hu) females had higher total cholesterol levels compared to h-B/A-II/A-I(Hu/Hu) females (895.08+/-183.07 mg/dl versus 544.43+/-116.42 mg/dl; p<0.05) and developed larger atherosclerotic lesions (148,260+/-78,924 microm(2) versus 54,132+/-43,204 microm(2), respectively; p<0.05). On the contrary, no difference in mean lesion area was found between h-B/A-II/A-I(M)(Hu/Hu) and h-B/A-II/A-I(Hu/Hu) males (19,779+/-6,098 microm(2) versus 15,706+/-13,095 microm(2); p=0.685). Our data suggest that, in the atherosclerosis-susceptible human apoB/A-II mouse model, expression of the human apoA-I(M) gene does not have protective advantage over that of the apoA-I gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16285990     DOI: 10.1016/j.atherosclerosis.2005.03.008

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  15 in total

1.  Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice.

Authors:  Mary G Sorci-Thomas; Manal Zabalawi; Manish S Bharadwaj; Ashley J Wilhelm; John S Owen; Bela F Asztalos; Shaila Bhat; Michael J Thomas
Journal:  Biochim Biophys Acta       Date:  2011-09-14

Review 2.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

Review 3.  HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology.

Authors:  Robert S Rosenson; H Bryan Brewer; Philip J Barter; Johan L M Björkegren; M John Chapman; Daniel Gaudet; Daniel Seung Kim; Eric Niesor; Kerry-Anne Rye; Frank M Sacks; Jean-Claude Tardif; Robert A Hegele
Journal:  Nat Rev Cardiol       Date:  2017-08-10       Impact factor: 32.419

4.  Conformation of dimeric apolipoprotein A-I milano on recombinant lipoprotein particles.

Authors:  Shaila Bhat; Mary G Sorci-Thomas; Laura Calabresi; Michael P Samuel; Michael J Thomas
Journal:  Biochemistry       Date:  2010-06-29       Impact factor: 3.162

5.  Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice.

Authors:  Nicholas F Fitz; Victor Tapias; Andrea A Cronican; Emilie L Castranio; Muzamil Saleem; Alexis Y Carter; Martina Lefterova; Iliya Lefterov; Radosveta Koldamova
Journal:  Brain       Date:  2015-10-28       Impact factor: 13.501

Review 6.  Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis.

Authors:  Jonathan D Smith
Journal:  Curr Opin Investig Drugs       Date:  2010-09

Review 7.  Targeting high density lipoproteins in the prevention of cardiovascular disease?

Authors:  Daniel B Larach; Emil M deGoma; Daniel J Rader
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

8.  Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano.

Authors:  Eric T Alexander; Ginny L Weibel; Michelle R Joshi; Charulatha Vedhachalam; Margarita de la Llera-Moya; George H Rothblat; Michael C Phillips; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

9.  Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.

Authors:  Yanhong Guo; Yanbo Fan; Jifeng Zhang; Gwen A Lomberk; Zhou Zhou; Lijie Sun; Angela J Mathison; Minerva T Garcia-Barrio; Ji Zhang; Lixia Zeng; Lei Li; Subramaniam Pennathur; Cristen J Willer; Daniel J Rader; Raul Urrutia; Y Eugene Chen
Journal:  J Clin Invest       Date:  2015-09-14       Impact factor: 14.808

10.  Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I.

Authors:  Eric T Alexander; Masafumi Tanaka; Momoe Kono; Hiroyuki Saito; Daniel J Rader; Michael C Phillips
Journal:  J Lipid Res       Date:  2009-03-24       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.